The relationship among plasma ghrelin level and H. pylori infection and eradication therapy in patients with chronic kidney disease

The relationship among plasma ghrelin level and H. pylori infection and eradication therapy in patients with chronic kidney disease - Ghrelin and H. pylori in chronic kidney disease patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000023336

Enrollment

300

Registered

2016-07-26

Start date

2012-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemodialysis patients and non-dialysis patients with chronic kidney disease

Interventions

H. pylori eradication therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)With chronic renal dysfunction including hemodialysis (2)Receiving gastroduodenal endoscopy

Exclusion criteria

Exclusion criteria: (1)Having a H. pylori eradication history (2)With history of gastrectomy (3)With significant clinical illness (e.g., cancer) (4)Lack of informed consent

Design outcomes

Primary

Measure	Time frame
Association with plasme ghrelin levels and gastric mucosal atrophy in hemodialysis patients	—

Secondary

Measure	Time frame
1)Association with plasme ghrelin levels and H. pylori infection in hemodialysis patients 2)H. pyloti infection rate in CKD patients 3)Association with plasme ghrelin levels and mutrition markers in CKD patients 4)Prevalence of the upper gastrointestinal disease in CKD patients 5)Eradication rate of H. pylori in CKD patients 6)Change of plasma ghlerin levels after eradicaion therapy 7)Change of nutrition markers after eradicaion therapy	—

Measure

Time frame

1)Association with plasme ghrelin levels and H. pylori infection in hemodialysis patients 2)H. pyloti infection rate in CKD patients 3)Association with plasme ghrelin levels and mutrition markers in CKD patients 4)Prevalence of the upper gastrointestinal disease in CKD patients 5)Eradication rate of H. pylori in CKD patients 6)Change of plasma ghlerin levels after eradicaion therapy 7)Change of nutrition markers after eradicaion therapy

—

Countries

Japan

Contacts

Public ContactHitomi Ichikawa

Hamamatsu University School of Medicine First Department of Mediine

hito0215@hama-med.ac.jp053-435-2261

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026